Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.
CONCLUSIONS
In this longitudinal study of 4,137 persons, bone mineral density was negatively associated with osteoprotegerin at baseline in both genders. In postmenopausal women not using hormone replacement therapy (HRT), bone-loss increased with increasing osteoprotegerin levels, whereas no relationship was found in men, premenopausal women, or postmenopausal women taking HRT.


BACKGROUND
In a population-based study of 2,003 men and 2,134 women, the relationship between the osteoprotegerin (OPG)/factor-kappaB ligand (RANKL) system and bone mineral density (BMD) and changes in BMD was examined.


METHODS
Baseline measurements included height, weight, BMD of the forearm, OPG, RANKL, vitamin D, and serum parathyroid hormone (PTH) and information about lifestyle, prevalent diseases, and use of medication. BMD was remeasured at follow-up 6 years later.


RESULTS
BMD was negatively associated with OPG at baseline in both men and women (p trend over OPG levels = 0.01 and 0.007, respectively, after adjustments for age, and other confounders). In postmenopausal women not on hormone replacement therapy, bone loss increased with increasing OPG (p = 0.005), whereas no relationship was found in men, premenopausal women, or postmenopausal women on HRT (p >or= 0.28). BMD at baseline and BMD changes were not related to RANKL levels in any of the groups (p >or= 0.14).


CONCLUSIONS
In postmenopausal women not using HRT, bone loss associated positively with OPG. The results indicate that in women deficient in sex steroids, the OPG/RANKL system may play an important counter regulatory role in order to avoid bone loss and maintain BMD. In men and women replete in sex steroids, the OPG/RANKL system was not associated with BMD.
Jørgensen
L
L
Institute of Community Medicine, University of Tromsø, 9037 Tromsø, Norway. lone.jorgensen@uit.no
Vik
A
A
Emaus
N
N
Brox
J
J
Hansen
J-B
JB
Mathiesen
E
E
Vestergaard
P
P
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D015519:Bone Density / Q000502:physiology; D001851:Bone Diseases, Metabolic / Q000097:blood* / Q000503:physiopathology; D015914:Estrogen Replacement Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D053244:Osteoprotegerin / Q000097:blood* / Q000502:physiology; D017698:Postmenopause / Q000097:blood / Q000502:physiology; D053245:RANK Ligand / Q000097:blood* / Q000502:physiology; D012737:Sex Factors
D053244:Osteoprotegerin; D053245:RANK Ligand; C505688:TNFSF11 protein, human
JAMA. 2004 Mar 3;291(9):1108-13
14996780
Nature. 1999 Jan 28;397(6717):315-23
9950424
J Clin Endocrinol Metab. 2007 Dec;92(12):4514-21
17895323
N Engl J Med. 2006 Feb 23;354(8):821-31
16495394
J Clin Endocrinol Metab. 2008 May;93(5):1789-95
18303076
Cell. 1998 Apr 17;93(2):165-76
9568710
Clin Endocrinol (Oxf). 2005 Jan;62(1):92-8
15638876
Osteoporos Int. 2005 Apr;16(4):417-23
15776220
J Clin Endocrinol Metab. 2002 Oct;87(10):4470-5
12364420
J Exp Med. 2000 Aug 21;192(4):463-74
10952716
Eur J Endocrinol. 2007 May;156(5):555-62
17468191
Clin Endocrinol (Oxf). 2005 Mar;62(3):349-53
15730418
Bone. 2005 Apr;36(4):727-35
15781001
Bone. 2003 Jun;32(6):681-6
12810175
J Bone Miner Res. 2001 Feb;16(2):348-60
11204435
Calcif Tissue Int. 2005 Jan;76(1):1-6
15455183
J Bone Miner Metab. 2004;22(2):132-8
14999524
Menopause. 2008 Mar-Apr;15(2):357-62
17925661
BMJ. 1996 May 18;312(7041):1254-9
8634613
Osteoporos Int. 2005 Nov;16(11):1368-74
15711777
Osteoporos Int. 1999;10(5):425-32
10591841
Circulation. 2005 May 17;111(19):2461-8
15883214
Osteoporos Int. 2005 Dec;16(12):1597-603
15886862
Endocrinology. 2001 Dec;142(12):5050-5
11713196
J Bone Miner Res. 1999 Apr;14(4):518-27
10234572
Calcif Tissue Int. 2006 Oct;79(4):207-13
17048067
J Clin Endocrinol Metab. 2003 Mar;88(3):1014-8
12629078
J Endocrinol Invest. 2008 Feb;31(2):163-8
18362509
J Clin Epidemiol. 2000 Nov;53(11):1104-12
11106883
Osteoporos Int. 2002 May;13(5):394-9
12086350
J Clin Endocrinol Metab. 2001 Jul;86(7):3162-5
11443182
Science. 2000 Sep 1;289(5484):1504-8
10968780
J Clin Endocrinol Metab. 2001 Feb;86(2):631-7
11158021
Clin Endocrinol (Oxf). 2004 Aug;61(2):244-9
15272921